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A B S T R A C T
Background
Bronchiectasis is an important cause of respiratory morbidity in both developing and developed countries. Antibiotics are considered
standard therapy in the treatment of this condition but it is unknown whether short courses (four weeks or less) are efficacious.
Objectives
To determine whether short courses of antibiotics (i.e. less than or equal to four weeks) for treatment of acute and stable state
bronchiectasis, in adults and children, are efficacious when compared to placebo or usual care.
Search methods
The Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library), MEDLINE, EMBASE, OLDMEDLINE,
CINAHL, AMED and PsycINFO and handsearching of respiratory journals and meeting abstracts were performed by the Cochrane
Airways Group up to February 2011.
Selection criteria
Only randomised controlled trials were considered. Adults and children with bronchiectasis (defined clinically or radiologically) were
included. Patients with cystic fibrosis were excluded.
Data collection and analysis
Two review authors independently reviewed the titles, abstracts and citations to assess eligibility for inclusion. Only one study fulfilled
the inclusion criteria and thus meta-analysis could not be performed.
Main results
The single eligible study showed a small benefit, when compared to placebo, of four weeks of inhaled antibiotic therapy in adults with
bronchiectasis and pseudomonas in their sputum. There were no studies in children and no studies on oral or intravenous antibiotics.
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Authors’ conclusions
There is insufficient evidence in the current literature to make reasonable conclusions about the efficacy of short course antibiotics in the
management of adults and children with bronchiectasis. Until further evidence is available, adherence to current treatment guidelines
is recommended.
P L A I N L A N G U A G E S U M M A R Y
Short courses of antibiotics for children and adults with bronchiectasis
There is a paucity of evidence to conclude whether short courses of antibiotics (i.e. less than or equal to four weeks) are equivalent or
superior to placebo in the treatment of stable or exacerbation state bronchiectasis. One single study showed some benefit of short-course
inhaled antibiotics over placebo, in terms of microbiological response and subjective improvement in medical condition, although this
was balanced against an increase in adverse effects and antimicrobial resistance in the treatment group. Given the potential benefits of
shorter duration antibiotic therapy in bronchiectasis, further RCTs are clearly needed to answer this important question.
B A C K G R O U N D
Non cystic-fibrosis bronchiectasis, previously termed an ’orphan
disease’ is increasingly recognised as a major cause of respira-
tory morbidity both in developing countries as well as affluent
countries, and particularly within Indigenous populations (Chang
2008; Edwards 2003; Singleton 2000).
There are many known aetiological associations with bronchiec-
tasis. Severe lower respiratory tract infection has previously been
identified as the most common preceding medical condition in
children diagnosed with bronchiectasis (Chang 2008b; Eastham
2004; Karakoc 2009; Singleton 2000), and continues to be amajor
cause of bronchiectasis worldwide (Callahan 2002; Edwards 2003;
Karakoc 2009). However, diseases that affect the pulmonary sys-
tem (such as immunodeficiency) have become increasingly identi-
fied as important causes of bronchiectasis within developed coun-
tries (Li 2005; Shoemark 2007).
In adults, the major aetiological associations include post-infec-
tion pneumonia or TB, primary ciliary dyskinesia, allergic bron-
chopulmonary aspergillosis and immunodeficiencies (Shoemark
2007). Primary lung diseases such as chronic obstructive pul-
monary disease (COPD) (O’Brien 2000; Patel 2004), sarcoido-
sis (Lewis 2002), and bronchiolitis obliterans (Chang 1998) have
been associated with bronchiectasis as a secondary manifestation.
In children, immunodeficiency, aspiration, primary ciliary dysk-
inesia and congenital airway anomalies are important consider-
ations (Li 2005). Despite intensive investigations, an underly-
ing cause is often not found in many children and adults with
bronchiectasis (Shoemark 2007).
Description of the condition
Bronchiectasis is a disease that primarily affects the airways in
the initial disease phase. The postulated pathophysiology includes
a ’vicious circle’ of infection, inflammation and impairment of
mucociliary clearance mechanisms eventually leading to airway
destruction and bronchial dilatation (Cole 1986).
Adult patients usually present with cough, daily sputum produc-
tion, dyspnoea, rhinosinusitis, haemoptysis and recurrent pleurisy
(King 2004). Children usually present with chronic wet cough or
recurrent pneumonia (Singleton 2000). They may have clinical
signs such as crackles and wheeze on chest auscultation and some-
times peripheral clubbing (King 2004). With appropriate treat-
ment (usually antibiotics and airway clearance), the chronic cough
can totally resolve (Kapur 2009), as can radiological evidence of
bronchiectasis (Gaillard 2003). High-resolution Computed To-
mography (HRCT) of the chest is considered the gold-standard in
diagnosis of bronchiectasis. However, controversy exists as to the
normal cut-off of broncho-arterial ratio (particularly in children)
(Chang 2008b). Hence, bronchiectasis is sometimes defined clin-
ically in children (Chang 2008b; Singleton 2000). Recent studies
suggest that volumetric scans acquired using multi-detector CT
are substantially more sensitive and accurate than conventional
HRCT for assessing bronchiectasis (Hill 2009).
A combination of airway clearance techniques and antibiotic
therapy, with or without other therapies such as anti-inflamma-
tory agents and bronchodilators, are current recommended treat-
ment for non-cystic fibrosis bronchiectasis (Chang 2008b). Spe-
cific treatments targeted to the underlying aetiology (such as in-
travenous immunoglobulin for common variable immunodefi-
ciency) is also important in the management of bronchiectasis.
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Early recognition and treatment of bronchiectasis may improve
long term outcomes (Kapur 2010).
Description of the intervention
Antibiotics are the mainstay of therapy in the management of
bronchiectasis (Prasad 2007). There are various methods to de-
liver antibiotics to the pulmonary system (oral, intravenous or in-
haled). The type of antibiotics given may be targeted to the pa-
tient’s known airway organism(s) or used empirically.
How the intervention might work
Infection and inflammation are key components in the aetiopatho-
genesis of bronchiectasis (Cole 1986). Bronchiectatic airways facil-
itate chronic bacterial colonisation and predispose them to recur-
rent infections (Loebinger 2007). Chronic bacterial infection elic-
its a systemic inflammatory response with local release of inflam-
matory cytokines (including TNF-α and IL-8) causing migration
of inflammatory cells such as neutrophils and lymphocytes (Gaga
1998; Shum 2000). Neutrophils release proteolytic enzymes e.g.
neutrophil elastase (Amitani 1995) and reactive oxygen species
(Anderson 1996), into the airway lumen which cause epithelial
damage and stimulate mucous production (Adler 1990). Antibi-
otics can potentially halt the bacterial infection and subsequently
limit ongoing neutrophilic inflammation.
An existing Cochrane Review found that prolonged courses of
antibiotics for bronchiectasis, i.e. greater than fourweeks in length,
are effective in reducing sputum volume and purulence but have
a limited impact on the natural history of the condition (Evans
2007). We have reviewed the literature to determine the impact of
shorter courses of antibiotics during stable state and exacerbation
state in bronchiectasis.
Why it is important to do this review
Most adults and children with bronchiectasis are given frequent
courses of antibiotics, the optimal duration of which is unknown.
The published Cochrane Review on antibiotics for bronchiectasis
is limited to prolonged courses greater than four weeks in duration
(Evans 2007).
In clinical practice, short courses of antibiotics during stable and
exacerbation states of bronchiectasis often result in improvement
in symptoms. Objective measures of airway inflammation also im-
prove, as some studies have shown, for example use of short-course
inhaled gentamicin resulted in improvement in airway hypersecre-
tion and inflammation (Lin 1997).
There is currently a paucity of evidence on the optimal duration
of antibiotics in stable and exacerbation states. However, there is
a trend towards use of shorter courses (i.e. less than two weeks)
amongst clinicians. The risks of antibiotic side effects and resis-
tance are a significant concern when using longer courses of an-
tibiotics. A review of the literature to determine the evidence for
use of shorter courses of antibiotics in adults and children in stable
and exacerbation states of bronchiectasis is important to assist in
guiding clinical practice.
O B J E C T I V E S
To evaluate the efficacy of short courses (i.e. four weeks or less) of
antibiotics in children and adults with bronchiectasis;
(a) during stable state bronchiectasis; and
(b) for reducing the severity and frequency of acute respiratory
exacerbations.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Any randomised controlled trial comparing outcomes with use of
antibiotics (intravenous, oral or inhaled) versus placebo or usual
care as the control, for periods of less than, or equal to, four weeks,
in non-cystic fibrosis bronchiectasis. Participants are allowed to
have adjunctive therapies (such as airway clearance) as long as they
have equal chance of having these adjunctive therapies.
Types of participants
Adults and children with bronchiectasis (defined clinically or ra-
diologically) not related to cystic fibrosis.
Types of interventions
Any short (four weeks or less) course of antibiotics given by intra-
venous, oral or nebulised routes.
Types of outcome measures
Primary outcomes
The primary outcome measures were change in:
1. Symptom score (e.g. bronchiectasis severity control, cough-
specific/respiratory-specific quality of life (QoL) or generic
health-specific QoL)
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2. Lung function indices (airway resistance or airway calibre
measurements)
3. Adverse events
Secondary outcomes
1. Sputum or airway markers (weight, purulence, colour
(Bronkotest), inflammatory profiles)
2. Microbiological data (density, resistance patterns)
3. Exacerbation data (length, time to next exacerbation)
Search methods for identification of studies
Electronic searches
Randomised controlled trials were identified using the Cochrane
Airways Group Specialised Register of trials, which is derived
from systematic searches of bibliographic databases including the
Cochrane Central Register of Controlled Trials (CENTRAL),
MEDLINE, EMBASE,OLDMEDLINE, CINAHL, AMEDand
PsycINFO, and handsearching of respiratory journals and meet-
ing abstracts (please see the Airways Group search methods for
further details). We searched all records in the Specialised Register
coded as ’bronchiectasis’ using the following terms:
antibiotic* OR *cillin OR *tetracycline OR *mycin OR
macrolide* OR quinolone* OR *oxacin OR trimethoprim OR
*sulpha OR *ceph or anti-bacteri* or “anti bacteri* OR anti-mi-
crobial* OR anti*
The search was conducted in February 2011.
Searching other resources
We handsearched all the papers and reviews identified for further
references and contacted authors to request their identification of
any unpublished ormissed trials.We contacted researchers directly
as required to establish whether other unpublished or ongoing
studies were available for assessment.We handsearched clinical tri-
als web sites (www.clinicalstudyresults.org; www.clinicaltrials.gov;
www.fda.gov).
Data collection and analysis
Selection of studies
Following electronic literature searches, AC and DW indepen-
dently reviewed the searches to identify potentially relevant trials
for full review. We searched bibliographies and texts to identify
additional studies. From the full text using specific criteria, AC
and DW independently selected trials for inclusion. There was
complete agreement between review authors.
Data extraction and management
We extracted information from each study for the following char-
acteristics:
1. Design (description of randomisation, blinding, allocation,
number of study centres and location, withdrawals)
2. Participants (N, mean age, age range of the study, baseline
lung function, duration of antibiotics < 4 weeks versus no
antibiotics)
3. Intervention (type and duration of antibiotic,
appropriateness of antibiotic choice, dosing schedules of groups)
4. Outcomes (type of outcomes and results of outcomes)
We requested further information from the trial authors where
required. This occurred with Barker 2000 as explained in the in-
cluded studies section of the Results.
Studies were translated to English where possible.
Assessment of risk of bias in included studies
We assessed trial bias protection in the following domains and
study quality according to whether studies met the following pre-
specified quality criteria (as met, unmet or unclear) using the risk
of bias (RoB) table in Review Manager 5.
1. Sequence generation
2. Allocation concealment
3. Blinding of participants and investigators
4. Loss to follow-up
Measures of treatment effect
We extracted data for each of the outcomes (where data were
available) from the trial publication that fulfilled the inclusion
criteria.
We performed an initial qualitative comparison of all the indi-
vidually analysed studies taking into account differences in study
populations, inclusion/exclusion criteria, interventions, outcome
assessment and estimated effect size, to examine whether pooling
of results (meta-analysis) was reasonable.
Unit of analysis issues
We sought to obtain data that were reported with patients (rather
than events) as the unit of analysis for the primary outcomes.
Dealing with missing data
The proportion of randomised patients who provided data for the
main outcomes was reported and we had planned to compare this
with the number of patients with events in each outcome category.
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Assessment of heterogeneity
Wehad planned to describe and explore heterogeneity between the
study results, and to use the 95% confidence interval, estimated
using a random-effectsmodel, whenever therewere concerns about
statistical heterogeneity.
Assessment of reporting biases
If combining data was possible, we had planned to assess publica-
tion bias using a funnel plot. We planned to identify and report
on any selective reporting in the included trials.
Data synthesis
We combined data using Review Manager 5, with a view to us-
ing a fixed-effect mean difference (calculated as a weighted mean
difference) for continuous data variables. If different scales were
combined, we had intended to use the standardised mean differ-
ence.
For the dichotomous outcome variables of each individual study,
we had planned to calculate odds ratios using a modified inten-
tion-to-treat analysis (i.e. failure assumed if participant drops out
of study). This analysis assumes that children or adults not avail-
able for outcome assessment have not improved (and probably
represents a conservative estimate of effect).
For the primary outcomes we intended to calculate a number
needed to treat (benefit or harm) when possible for the different
levels of risk as represented by control group event rates over a
specified time period using the pooled Odds Ratio and its confi-
dence interval using an online calculator, Visual Rx (Cates 2003).
A summary of findings (SoF) table would be constructed for the
primary outcomes.
Subgroup analysis and investigation of heterogeneity
We had intended to perform an a priori subgroup analysis for:
1. Children versus adults (adult studies will be considered as
those which recruited participants from 18 years upwards)
2. Type of antibiotics (oral, intravenous, inhaled)
3. Type of control arm (placebo/no treatment or control
antibiotic i.e. prolonged duration antibiotics)
4. State during enrolment (stable state or exacerbation)
Sensitivity analysis
Sensitivity analyses were also planned to assess the impact of the
potentially important factors on the overall outcomes:
1. variation in the inclusion criteria;
2. differences in the medications used in the intervention and
comparison groups;
3. analysis using random-effects model;
4. analysis by ”treatment received“; and
5. analysis by ”intention-to-treat“.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
From the searches, the Cochrane Airways Group specialised reg-
ister/search identified 187 potentially relevant titles. After assess-
ing the titles/abstracts, we obtained19 papers for consideration for
inclusion in the review. We reviewed 11 full text articles and 8
further abstracts. We excluded 18 studies (see Excluded studies).
We found two potentially eligible studies, however they appeared
to have used the same patient population, leaving only one eligible
study in adults. We identified no studies in children.
Included studies
The included studies were Barker 2000 and Couch 2001a, which
described the same study populations. Couch 2001a was an ”early
review of data“ for a chest supplement on aerosolised therapeutics
as discussed by Fiel 2001 in his editorial. For this reason, we used
the final data in Barker’s paper in this Cochrane Review.
The sole study was a multicentre parallel RCT that examined the
effect of nebulised tobramycin (Tobramycin Solution for Inhala-
tion) versus placebo, in adults with CT confirmed bronchiectasis
and Pseudomonas aeruginosa infection. There were 16 study sites,
74 adults enrolled with completion rate of 81% (60/74). Further
details are described in the Characteristics of included studies.
Excluded studies
Eighteen studies were excluded as they did not fulfil criteria for
the review. Fifteen of the eighteen studies excluded had no suitable
comparator/placebo group, one study did not specify bronchiec-
tasis as an inclusion criterion, one study had treatment periods
greater than four weeks, two studies shared a common study pop-
ulation, resulting in the exclusion of one.
Bilton 2006 and Shrewsbury 2004 examined short courses of an-
tibiotics in bronchiectasis and compared oral ciprofloxacin (in
treatment doses) plus placebo to oral ciprofloxacin plus inhaled
tobramycin. Although these studies almost fulfilled criteria for in-
clusion, there was no ”antibiotic-free“ placebo for comparison, re-
sulting in their exclusion from this review.
Couch 2001a was excluded as it was an early review of the same
data used in the included study Barker 2000. Attempts to con-
tact the corresponding author were unsuccessful, but this was con-
firmed in the editorial Fiel 2001 which accompanied the paper.
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Risk of bias in included studies
Allocation concealment was unclear in this study (Barker 2000).
Block randomisationwas utilised to balance group sizes. The study
was double-blinded,with both investigators andparticipants being
blinded to study group allocation to reduce selection bias. Six
patients were withdrawn from the placebo group due to need for
an antibiotic other than the study drug.
Allocation
Block randomisation of patients was used. Eligible patients were
randomly assigned in blocks of two to parallel groups at each study
centre to receive either inhaled tobramycin or placebo.
Blinding
The study was double-blinded i.e. both participants and investiga-
tors were blinded to the study drug assignment until completion
of the follow-up visit and data were collected from all study sites.
The placebo used (quinine sulphate) was chosen because of its
similar taste to tobramycin. It was unclear whether investigators
were blinded to the study hypothesis.
Incomplete outcome data
The number of participants withdrawn (due to adverse events
or use of antibiotic other than the study drug) and those lost to
follow-up were reported for both inhaled tobramycin and placebo
groups.
Selective reporting
There was no suggestion that selective reporting had occurred.
Effects of interventions
The included trial involved 74 patients with 60 completing the
study. In the absence of additional suitable studies, there were
insufficient data to perform a meta-analysis. The outcomes from
the single study (also presented in the forest plot) were:
Primary Outcomes
1. Symptom score (e.g. bronchiectasis severity control,
cough-specific/respiratory-specific quality of life (QoL) or
generic health-specific QoL)
The study did not specificallymeasure any symptoms to determine
a symptom score. Instead, the investigator’s subjective assessment
of a change in the patient’s general medical condition (”improved“
or ”not improved“) was recorded at week six: 23 of 37 (62%)
patients in the tobramycin-treated group significantly improved
compared to 14 of 35 (40%) in the placebo group that improved
(Analysis 1.1; OR 0.37; 95% CI 0.14 to 0.95).
2. Lung function indices (airway resistance or airway calibre
measurements)
Percent change in forced expiratory volume in one second (FEV1)
percent predicted and in Forced Vital Capacity (FVC) percent
predicted from baseline to week four were not statistically signif-
icant between the tobramycin and placebo groups (-2.2% versus
1.5% respectively, P = 0.41) for FEV1 % predicted and FVC %
predicted (-2.8% versus 2.2%, P = 0.19). Airway reactivity (per-
cent change in FEV1 from pre- to post-study drug administration)
was not significantly different from zero percent for either the to-
bramycin group (mean = -1%, Week 0, -3% Week 4) or placebo
group (mean = -3% Week 0, -1% Week 4).
3. Adverse events
Thirty-one of 37 (84%) patients in each treatment group re-
ported at least one adverse event. Respiratory system adverse events
were reported by 26 (70%) tobramycin patients and by 19 (51%)
placebo patients. There was no statistical significance, but results
favoured the placebo group (OR 2.24; 95% CI 0.86 to 5.82;
Analysis 2.1). Five patients in the tobramycin group and one pa-
tient in the placebo group were hospitalised and treated for an
exacerbation of their pulmonary disease (OR 5.63; 95% CI 0.62
to 50.73; Analysis 2.2).
Secondary outcomes
1. Microbiological response (i.e. change in P. aeruginosa
density from baseline to week 4 and week 6 and antibiotic
resistance)
At the endof the trial, significantlymore subjects in the tobramycin
group (13 of 37) had P. aeruginosa eradicated from their sputum
compared to the placebo group (0 of 37); (OR 0.03; 95% CI 0.01
to 0.14; Analysis 3.1.) Furthermore, a further 12 patients in the
tobramycin group had reduced P. aeruginosa carriage (PA cfu/g
decreased by at least 2 log10 at week 4), compared to two patients
with reduced carriage in the placebo group.
However, at follow-up two weeks post cessation of antibiotics,
the mean reduction in the tobramycin group was smaller than
in previous weeks, suggesting some regrowth of organisms after
ceasing the antibiotic.
Four of 36 patients in the tobramycin group and one of 32 in the
placebo group, who began the study with susceptible P. aeruginosa,
had resistant P. aeruginosa at their last visit (P = 0.36). Three of the
four patients in the tobramycin group who developed resistant P.
aeruginosa showed no microbiological response. All four patients
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were considered to have not improved when their general medical
condition was assessed.
D I S C U S S I O N
This review is limited to a sole study in adults. The data suggest
that short term inhaled antibiotics show some benefit in the treat-
ment of patients with bronchiectasis and P. aeruginosa. The study
followed the patients for only two weeks post-treatment to as-
sess longevity of response. Despite its weaknesses, this single study
supports previous Cochrane Reviews on the use of longer term
antibiotics in bronchiectasis (Evans 2007), in showing subjective
improvement in general medical condition as assessed by an in-
vestigator.
This review has highlighted the fact that, although antibiotics are
themainstay of treatment in adults and children with bronchiecta-
sis, there remains a paucity of data, particularly high quality data,
to support this practice. In today’s evidence based medical era and
with bronchiectasis becoming increasingly recognised as a major
cause of respiratory morbidity, there will be an increasing need to
provide evidence-based answers to these common questions.
A small number of patients in the study antibiotic arm developed
”resistant“ pseudomonas. This highlights an important compli-
cation of antibiotic therapy, particularly when antibiotic use in
any one patient is prolonged or recurrent. Previous research by
Hillier 2007 has shown that antibiotic resistance increases with
increased duration of antibiotic therapy. These findings are related
to urinary tract infections but are likely to be applicable to infec-
tions elsewhere in the body including the lung. This issue, com-
bined with the likely improved quality of life for patients receiv-
ing shorter courses of antibiotics, highlights the need for further
studies to determine the optimal duration of antibiotic therapy in
bronchiectasis.
The included study followed patients for only two weeks post-
therapy. Given that antibiotics are known to indirectly limit neu-
trophilic inflammation in the airways and ideally eradicate the bac-
terial infection, it is not surprising that patients showed improve-
ment over this follow-up period. It is unknown if two weeks is an
optimal timeframe to assess bacterial eradication adding further
to the limitations of this study. To assess longevity of symptom
response and microbiological eradication, a longer timeframe of
follow-up would have been required.
Evans 2007’s Cochrane Review on prolonged antibiotics found
a significant benefit of prolonged antibiotics (i.e. four or more
weeks) in terms of response rates. They found no significant differ-
ence between placebo and prolonged antibiotics in terms of exac-
erbation rates and lung function. This would concur with Barker
2000, which found a subjective improvement in patients’ general
medical condition with inhaled tobramycin therapy as compared
to placebo, with no significant differences in lung function be-
tween treatment groups.
The single included study (Barker 2000) showed some benefit of
four weeks of inhaled antibiotic therapy compared with placebo
in patients with bronchiectasis and P. aeruginosa infection in terms
of microbiological response (at the expense of increased resistance)
and improvement in general medical condition. The lack of other
suitable studies for this Cochrane Review precluded a meta-analy-
sis, and as a result we could not draw any firm conclusions on the
topic.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
When considering implications for practice, one must acknowl-
edge the fact that this review was based on one study of adult pa-
tients and the intervention was ”inhaled“ antibiotics. This study
showed a small benefit in microbiological response and overall
subjective improvement in general medical condition, with no ef-
fect on lung function and an increase in adverse events in the in-
tervention group. The study failed to address primary outcome
measures with symptom scores or objective outcomes. Therefore,
although this one study is suggestive of benefit of short courses
of antibiotics for bronchiectasis, one would conclude, for current
practice implications, that there is insufficient evidence available
in the current literature tomake any reasonable conclusions. How-
ever until further evidence is available, clinicians should adhere
to guidelines (Chang 2010; Pasteur 2010) that include data from
non RCTs.
Implications for research
Well-designed, double-blinded, parallel, randomised controlled
trials are required to assess the role of short courses of antibiotics
in the treatment of bronchiectasis. These studies should include
validated outcome measures such as improvements in symptom
score, QOL and lung function, balanced against adverse effects
as primary outcome measures. Trials including oral, inhaled and
intravenous antibiotic administration methods are needed. Future
RCTs should be undertaken in paediatric as well as adult patients.
Well-designed studies should include sufficient longitudinal fol-
low-up of patients to assess longevity of intervention response and
therefore applicability of evidence to practice. Such well-designed
research would have the potential to improve the quality of life for
individuals with bronchiectasis.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Barker 2000
Methods The study was a randomised placebo-controlled, double-blinded trial with antibiotics
administered for 4 weeks. Eligible patients were randomly assigned in blocks of two
to parallel groups at each of 16 study sites across the United States to receive either
Tobramycin solution for inhalation or placebo. This was administered twice daily for 4
weeks in bronchiectasis patients whose sputum contained Pseudomonas aeruginosa. Pa-
tients were then observed for 2 weeks after administration of their last dose. Of patients
enrolled, they were divided equally between the two treatment groups. Patients were
withdrawn if they required any additional antibiotics at any stage during study partici-
pation
Patients were screened 2 weeks prior to their initial dose of the study drug, were dosed
for 4 weeks, and then observed for 2 weeks after their last dose. Thus the total duration
of the study was 8 weeks. At each visit a sputum sample was obtained and the density
of the P. aeruginosa in sputum was measured. Pulmonary function testing (FEV1 and
FVC) was performed at baseline and at the final treatment visit (week 4). Tobramycin
levels were measured. Adherence was measured at week 4 by counting the number of
vials of study drug used. A subjective clinical assessment of the patient’s general medical
condition was made, by a study investigator, at the follow-up visit on week 6
There were 6 patients who withdrew from the tobramycin group (3 for adverse events,
2 for use of antibiotics other than study drug, and 1 was lost to follow-up.) 8 withdrew
from the placebo group (2 for adverse events, and 6 for use of antibiotics other than the
study drug.)
Participants 125 patients were screened and 74 patients (45 female), mean age 66.6 (tobramycin
group) and 63.2 (placebo group) were enrolled. Patients were block randomised to receive
either 300 mg of inhaled tobramycin or placebo twice daily for 4 weeks. 37 received
inhaled tobramycin and 37 received placebo
Inclusion: Bronchiectasis diagnosed by conventional or high-resolution CT and sputum
containing at least 104 cfu/mL P. aeruginosa.
Exclusion: cystic fibrosis, allergic bronchopulmonary aspergillosis, acute pulmonary pro-
cess requiring medical intervention as indicated by a new infiltrate on a chest radiograph,
significant recent haemoptysis, or had received antibiotics within 2 weeks of the screen-
ing visit
Interventions Nebulised tobramycin solution for inhalation (300mg tobramycin) twice daily or placebo
for 4 weeks
Outcomes Primary end point was (1) Change in P. aeruginosa density from baseline to week 4.
Additional endpoints included: (1) change in P. aeruginosa density from baseline values
to week 2 and to week 6; (2) an investigator’s subjective assessment of a change in
the patient’s general medical condition (”improved“ or ”not improved“) was made and
recorded at week 6, (3) the percent change in FEV1percent predicted and in FVCpercent
predicted from week 0 to week 4 and (4) Safety endpoints included the incidence of
adverse events, change in serum chemistry and haematology measurements, and airway
reactivity
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Barker 2000 (Continued)
Each patient’s microbiological response was categorised according to whether P. aerugi-
nosawas eradicated, reduced by treatment, or did not respond to treatment. P. aeruginosa
was considered eradicated if it was not detected at week 6 or if it was not detected at
week 4 and the patient was unable to produce sputum at week 6. A patient’s response was
defined as reduced by treatment if P. aeruginosa was recovered from the week 6 sputum
and reduced by at least 2 log 10 cfu/g at week 4 compared with baseline. A patient had
no microbiological response if P. aeruginosa did not decrease 2 log 10 cfu/g at week 4 or
if the patient withdrew from the study
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk Unclear
Blinding of participants and investigators. Low risk Patients and investigators were blinded to
the study drug assignment
Incomplete outcome data assessed? Low risk Number of dropouts and loss to follow-up
included.
Free of selective reporting? Low risk No suggestion that selective reporting may
have occurred.
Free of other bias? Low risk No other bias identified
Sequence generation. Low risk Sequence generation was referred to, how-
ever details were not provided
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bilton 2006 No suitable placebo/comparator group. (Comparator was not adequate to satisfy inclusion criteria, i.e. no
”antibiotic-free/placebo“ or long-term antibiotic group for comparison.)
Chrysanthopoulos 1989 No suitable placebo/comparator group.
Couch 2001a Overlap of study participants with included study.
Douglas 1957 No suitable placebo/comparator group.
Howie 1976 Study participants had unknown bronchiectasis status.
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(Continued)
Lam 1989 No suitable placebo/comparator group.
Lin 1996 No suitable placebo/comparator group.
Matsumoto 1986 No suitable placebo/comparator group. Not an RCT.
May 1972 No suitable placebo/comparator group.
Mehta 1991 No suitable placebo/comparator group.
Messens 1973 Translated from French. No suitable placebo/comparator group
Mijuskovic 1972 No suitable placebo/comparator group.
Nagy 1968 No suitable placebo/comparator group. (Compared antibiotic treatment to surgery.)
Oki 1993 No suitable placebo/comparator group. (Examined long term antibiotic treatment, no short course treat-
ment arm.)
Santiveri 1995 No suitable placebo/comparator group.
Shrewsbury 2004 No suitable placebo/comparator group. (Comparator was not adequate to satisfy inclusion criteria, i.e. no
”antibiotic-free/placebo“ or long-term antibiotic group for comparison.)
Tagaya 2002 No suitable placebo/comparator group.
Twiss 2008 Longer-course antibiotics (i.e. 2 to 3 months) compared to placebo. No short course group
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D A T A A N D A N A L Y S E S
Comparison 1. Change in general medical condition
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Improvement in general medical
condition
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
Comparison 2. Respiratory system adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Respiratory system adverse
events
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2 Hospitalised for respiratory
events
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
Comparison 3. Microbiological response
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological response 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
Comparison 4. Development of pseudomonas resistance (when initially sensitive)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pseudomonas resistance 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
14Short courses of antibiotics for children and adults with bronchiectasis (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.1. Comparison 1 Change in general medical condition, Outcome 1 Improvement in general
medical condition.
Review: Short courses of antibiotics for children and adults with bronchiectasis
Comparison: 1 Change in general medical condition
Outcome: 1 Improvement in general medical condition
Study or subgroup TSI Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Barker 2000 14/37 23/37 0.37 [ 0.14, 0.95 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 14 (TSI), 23 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours TSI Favours placebo
Analysis 2.1. Comparison 2 Respiratory system adverse events, Outcome 1 Respiratory system adverse
events.
Review: Short courses of antibiotics for children and adults with bronchiectasis
Comparison: 2 Respiratory system adverse events
Outcome: 1 Respiratory system adverse events
Study or subgroup TSI Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Barker 2000 26/37 19/37 2.24 [ 0.86, 5.82 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 26 (TSI), 19 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours TSI Favours placebo
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Analysis 2.2. Comparison 2 Respiratory system adverse events, Outcome 2 Hospitalised for respiratory
events.
Review: Short courses of antibiotics for children and adults with bronchiectasis
Comparison: 2 Respiratory system adverse events
Outcome: 2 Hospitalised for respiratory events
Study or subgroup Tobramycin Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Barker 2000 5/37 1/37 5.63 [ 0.62, 50.73 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 5 (Tobramycin), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 3.1. Comparison 3 Microbiological response, Outcome 1 Microbiological response.
Review: Short courses of antibiotics for children and adults with bronchiectasis
Comparison: 3 Microbiological response
Outcome: 1 Microbiological response
Study or subgroup TSI Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Barker 2000 12/37 33/35 0.03 [ 0.01, 0.14 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 12 (TSI), 33 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours TSI Favours placebo
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Analysis 4.1. Comparison 4 Development of pseudomonas resistance (when initially sensitive), Outcome 1
Pseudomonas resistance.
Review: Short courses of antibiotics for children and adults with bronchiectasis
Comparison: 4 Development of pseudomonas resistance (when initially sensitive)
Outcome: 1 Pseudomonas resistance
Study or subgroup TSI Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Barker 2000 4/36 1/32 3.88 [ 0.41, 36.63 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 4 (TSI), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours experimental Favours control
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